Home > Healthcare > Medical Devices > Implantable Devices > Implantable Cardioverter Defibrillators Market

Implantable Cardioverter Defibrillators Market Trends

Report ID: GMI7696
Published Date: Dec 2023
Report Format: PDF

Download Free Sample

Implantable Cardioverter Defibrillators Market Trends

Growing demand for combination ICD devices with pacemaker functionality, increased focus on patient-centric care, continuous advancements in wireless charging and battery technology are among the key variables propelling the product demand. Additionally, surging need for integration of artificial intelligence (AI) in healthcare and data analytics into ICD systems are other factors that are contributing to the evolving landscape of the implantable cardioverter defibrillators industry.

Miniaturization, longer battery life, leadless devices, and enhanced programming capabilities are all ongoing advances in ICD technology. These advancements endeavor to render ICDs more efficient, long-lasting, and patient-friendly.
Moreover, combination devices that integrate both ICD and pacemakers’ functions are becoming more prevalent. These devices offer comprehensive cardiac care for patients who require both defibrillation and pacing capabilities.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Market size for implantable cardioverter defibrillators surpassed USD 8.8 billion in 2023 and is projected to reach USD 15.9 billion by 2032 driven by the rising incidences of cardiovascular diseases, growing geriatric population, and continual technological advancements.

The biventricular devices segment held more than 42% share of the implantable cardioverter defibrillators industry in 2023 and is estimated to record substantial growth through 2032 owing to its increasing use among patients with heart failure and conduction abnormalities.

North America industry size for implantable cardioverter defibrillators was worth USD 4.7 billion in revenue in 2023 and is set to exhibit robust growth through 2032 driven by the ongoing adoption of state-of-the-art devices in the region.

Some of the leading implantable cardioverter defibrillator companies are Abbott Laboratories, Medtronic plc, BIOTRONIK SE & Co. KG, Boston Scientific Corporation, MicroPort Scientific Corporation, LivaNova plc, Koninklijke Philips N.V., CU Medical Germany GmbH, and MEDIANA Co., Ltd.